Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.38 |
| ▸ | RAF1 | P04049 | 3/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450821 | 0.90 | KDR (0.41) | BRAFRAF1PDE10ACSNK1A1CSNK1D | |
| SCHEMBL4812783 | 0.72 | TRPV1 (0.47) | PDE10ACSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL5456410 | 0.72 | MAPT (0.39) | BRAFRAF1KDR | |
| SCHEMBL5449915 | 0.71 | PDE10A (0.34) | BRAFRAF1PDE10ACSNK1A1CSNK1D | |
| SCHEMBL5763116 | 0.69 | RAF1 (0.32) | BRAFRAF1PDE10ACSNK1A1CSNK1D | |
| SCHEMBL5452404 | 0.69 | PIM1 (0.37) | BRAFRAF1PDE10ACSNK1A1CSNK1D | |
| SCHEMBL5457073 | 0.69 | RIPK1 (0.36) | BRAFRAF1PDE10ACSNK1A1CSNK1D | |
| SCHEMBL5444075 | 0.68 | KDR (0.41) | BRAFRAF1PDE10ACSNK1A1CSNK1D | |
| SCHEMBL4170603 | 0.67 | KDR (0.52) | BRAFRAF1PDE10ACSNK1A1CSNK1D | |
| SCHEMBL5444098 | 0.67 | KDM4E (0.46) | BRAFRAF1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021456-A1 | Aminobenzimidazole derivatives | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | claimed |
| EP-1656377-A1 | AMINOBENZIMIDAZOLE DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-05-17 | — | — | EP | claimed |
| WO-2005019216-A1 | AMINOBENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-03-03 | — | — | WO | claimed |
| US-20070021456-A1 | Aminobenzimidazole derivatives | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021456-A1 | Aminobenzimidazole derivatives | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021456-A1 | Aminobenzimidazole derivatives | TIE1, KDR, FLT1 | BRAF 22/4885RAF1 17/4885PDE10A 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.